Several antibodies blocking PD-1 signaling by either binding to PD-1 or to PD-L1 have shown clinical efficacy in solid tumors and hematological malignancies such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head, and neck squamous cell carcinoma, cervical cancer, uterine cancer, breast cancer, Merkel cell carcinoma, Hodgkin's lymphoma, diffuse large B cell lymphoma, and follicular lymphoma (39). Here, CD274 is linked to non-small cell lung carcinoma.